Coherus BioSciences Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
CHRS$0.82+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Three Months Ended | ||||||
| · · March 31, | ||||||
| · 2024 · 2023 | ||||||
| Net revenue | | $77,063 | | $32,436 | ||
| Costs and expenses: | | | | | ||
| Cost of goods sold | | 34,586 | | 16,874 | ||
| Research and development | | 28,470 | | 34,154 | ||
| Selling, general and administrative | | 56,532 | | 49,153 | ||
| Total costs and expenses | | 119,588 | | 100,181 | ||
| Loss from operations | | (42,525) | | (67,745) | ||
| Interest expense | | (11,116) | | (9,712) | ||
| Gain on Sale Transaction, net (Note 6) | | | 153,647 | | | — |
| Other income (expense), net | | 2,869 | | 1,728 | ||
| Income (loss) before income taxes | | 102,875 | | (75,729) | ||
| Income tax provision | | — | | — | ||
| Net income (loss) | | $102,875 | | $(75,729) | ||
| | | | ||||
| Net income (loss) per share: | | | | |||
| Basic | | $0.91 | | $(0.96) | ||
| Diluted | | $0.83 | | $(0.96) | ||
| | | | | | | |
| Weighted-average number of shares used in computing net income (loss) per share: | | | | | | |
| Basic | | | 112,749,306 | | | 79,268,853 |
| Diluted | | 125,529,971 | | 79,268,853 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.